



Recipient Information	Federal Award Information
<b>1. Recipient Name</b> ECOHEALTH ALLIANCE INC. 520 8TH AVE RM 1200  NEW YORK, 10018  <b>2. Congressional District of Recipient</b> 12  <b>3. Payment System Identifier (ID)</b> 1311726494A1  <b>4. Employer Identification Number (EIN)</b> 311726494  <b>5. Data Universal Numbering System (DUNS)</b> 077090066  <b>6. Recipient's Unique Entity Identifier</b> TKS7NBB4JDN6  <b>7. Project Director or Principal Investigator</b> Peter Daszak, PHD Executive Director daszak@ecohealthalliance.org 212-380-4460  <b>8. Authorized Official</b> Dr. Peter Daszak daszak@ecohealthalliance.org 212-380-4460	<b>11. Award Number</b> 1R01AI163118-01A1  <b>12. Unique Federal Award Identification Number (FAIN)</b> R01AI163118  <b>13. Statutory Authority</b> 42 USC 241 42 CFR 52  <b>14. Federal Award Project Title</b> Analyzing the potential for future bat coronavirus emergence in Myanmar, Laos, and Vietnam  <b>15. Assistance Listing Number</b> 93.855  <b>16. Assistance Listing Program Title</b> Allergy and Infectious Diseases Research  <b>17. Award Action Type</b> New Competing  <b>18. Is the Award R&amp;D?</b> Yes
<b>Federal Agency Information</b> <b>9. Awarding Agency Contact Information</b> Shaun W Gratton Grants Management Specialist NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES Shaun.Gratton@nih.gov 240-627-3594  <b>10. Program Official Contact Information</b> Erik J. Stemmy Program Officer NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES erik.stemmy@nih.gov 240-627-3380	<b>19. Budget Period Start Date 09-21-2022 – End Date 08-31-2023</b> <b>20. Total Amount of Federal Funds Obligated by this Action</b> \$653,392 20 a. Direct Cost Amount \$519,377 20 b. Indirect Cost Amount \$134,015  <b>21. Authorized Carryover</b> <b>22. Offset</b> <b>23. Total Amount of Federal Funds Obligated this budget period</b> \$653,392 <b>24. Total Approved Cost Sharing or Matching, where applicable</b> \$0 <b>25. Total Federal and Non-Federal Approved this Budget Period</b> \$653,392 ----- <b>26. Project Period Start Date 09-21-2022 – End Date 08-31-2027</b> <b>27. Total Amount of the Federal Award including Approved Cost Sharing or Matching this Project Period</b> \$653,392  <b>28. Authorized Treatment of Program Income</b> Additional Costs  <b>29. Grants Management Officer - Signature</b> Vandhana Khurana
<b>30. Remarks</b> Acceptance of this award, including the "Terms and Conditions," is acknowledged by the recipient when funds are drawn down or otherwise	

---

requested from the grant payment system.



RESEARCH  
Department of Health and Human Services  
National Institutes of Health

Notice of Award



NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

---

**SECTION I – AWARD DATA – 1R01AI163118-01A1**

**Principal Investigator(s):**

Peter Daszak, PHD

**Award e-mailed to:** [chmura@ecohealthalliance.org](mailto:chmura@ecohealthalliance.org)

Dear Authorized Official:

The National Institutes of Health hereby awards a grant in the amount of \$653,392 (see “Award Calculation” in Section I and “Terms and Conditions” in Section III) to EcoHealth Alliance in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award, including the "Terms and Conditions," is acknowledged by the recipient when funds are drawn down or otherwise requested from the grant payment system.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as “Research reported in this publication was supported by the National Institute Of Allergy And Infectious Diseases of the National Institutes of Health under Award Number R01AI163118. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.” Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

Award recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from an Investigator’s Financial Conflict of Interest (FCOI), in accordance with the 2011 revised regulation at 42 CFR Part 50 Subpart F. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the NIH website <http://grants.nih.gov/grants/policy/coi/> for a link to the regulation and additional important information.

If you have any questions about this award, please direct questions to the Federal Agency contacts.

Sincerely yours,

Vandhana Khurana  
Grants Management Officer  
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

Additional information follows

---

---

**Cumulative Award Calculations for this Budget Period (U.S. Dollars)**

Salaries and Wages	\$106,941
Fringe Benefits	\$37,387
Personnel Costs (Subtotal)	\$144,328
Consultant Services	\$18,864
Materials & Supplies	\$35,590
Travel	\$29,062
Subawards/Consortium/Contractual Costs	\$289,293
Publication Costs	\$2,240
Federal Direct Costs	\$519,377
Federal F&A Costs	\$134,015
Approved Budget	\$653,392
Total Amount of Federal Funds Authorized (Federal Share)	\$653,392
<b>TOTAL FEDERAL AWARD AMOUNT</b>	<b>\$653,392</b>
<b>AMOUNT OF THIS ACTION (FEDERAL SHARE)</b>	<b>\$653,392</b>

SUMMARY TOTALS FOR ALL YEARS (for this Document Number)		
YR	THIS AWARD	CUMULATIVE TOTALS
1	\$653,392	\$653,392
2	\$615,845	\$615,845
3	\$610,974	\$610,974
4	\$612,175	\$612,175
5	\$611,192	\$611,192

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

**Fiscal Information:**

**Payment System Identifier:** 1311726494A1  
**Document Number:** RA1163118A  
**PMS Account Type:** P (Subaccount)  
**Fiscal Year:** 2022

IC	CAN	2022	2023	2024	2025	2026
AI	8472364	\$653,392	\$615,845	\$610,974	\$612,175	\$611,192

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

**NIH Administrative Data:**

**PCC:** M51C S / **OC:** 41021 / **Released:** Gratton, Shaun 09-21-2022  
**Award Processed:** 09/22/2022 12:07:58 AM

---

**SECTION II – PAYMENT/HOTLINE INFORMATION – 1R01AI163118-01A1**

For payment and HHS Office of Inspector General Hotline information, see the NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm>

---

**SECTION III – STANDARD TERMS AND CONDITIONS – 1R01AI163118-01A1**

This award is based on the application submitted to, and as approved by, NIH on the above-titled project and is subject to the terms and conditions incorporated either directly or by reference in the following:

- a. The grant program legislation and program regulation cited in this Notice of Award.
- b. Conditions on activities and expenditure of funds in other statutory requirements, such as those included in appropriations acts.
- c. 45 CFR Part 75.
- d. National Policy Requirements and all other requirements described in the NIH Grants Policy Statement, including addenda in effect as of the beginning date of the budget period.
- e. Federal Award Performance Goals: As required by the periodic report in the RPPR or in the final progress report when applicable.
- f. This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

(See NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm> for certain references cited above.)

**Research and Development (R&D):** All awards issued by the National Institutes of Health (NIH) meet the definition of "Research and Development" at 45 CFR Part§ 75.2. As such, auditees should identify NIH awards as part of the R&D cluster on the Schedule of Expenditures of Federal Awards (SEFA). The auditor should test NIH awards for compliance as instructed in Part V, Clusters of Programs. NIH recognizes that some awards may have another classification for purposes of indirect costs. The auditor is not required to report the disconnect (i.e., the award is classified as R&D for Federal Audit Requirement purposes but non-research for indirect cost rate purposes), unless the auditee is charging indirect costs at a rate other than the rate(s) specified in the award document(s).

Carry over of an unobligated balance into the next budget period requires Grants Management Officer prior approval.

This grant is excluded from Streamlined Noncompeting Award Procedures (SNAP).

This award is subject to the requirements of 2 CFR Part 25 for institutions to obtain a unique entity identifier (UEI) and maintain an active registration in the System for Award Management (SAM). Should a consortium/subaward be issued under this award, a UEI requirement must be included. See <http://grants.nih.gov/grants/policy/awardconditions.htm> for the full NIH award term implementing this requirement and other additional information.

This award has been assigned the Federal Award Identification Number (FAIN) R01AI163118. Recipients must document the assigned FAIN on each consortium/subaward issued under this award.

Based on the project period start date of this project, this award is likely subject to the Transparency Act subaward and executive compensation reporting requirement of 2 CFR Part 170. There are conditions that may exclude this award; see <http://grants.nih.gov/grants/policy/awardconditions.htm> for additional award applicability information.

In accordance with P.L. 110-161, compliance with the NIH Public Access Policy is now mandatory. For more information, see NOT-OD-08-033 and the Public Access website: <http://publicaccess.nih.gov/>.

In accordance with the regulatory requirements provided at 45 CFR 75.113 and Appendix XII to 45 CFR Part 75, recipients that have currently active Federal grants, cooperative agreements, and procurement contracts with cumulative total value greater than \$10,000,000 must report and maintain information in the System for Award Management (SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached final disposition within the most recent five-year period. The recipient must also make semiannual disclosures regarding such

proceedings. Proceedings information will be made publicly available in the designated integrity and performance system (currently the Federal Awardee Performance and Integrity Information System (FAPIIS)). Full reporting requirements and procedures are found in Appendix XII to 45 CFR Part 75. This term does not apply to NIH fellowships.

**Treatment of Program Income:**

Additional Costs

---

**SECTION IV – AI SPECIFIC AWARD CONDITIONS – 1R01AI163118-01A1**

Clinical Trial Indicator: No

This award does not support any NIH-defined Clinical Trials. See the NIH Grants Policy Statement Section 1.2 for NIH definition of Clinical Trial.

THIS AWARD CONTAINS GRANT SPECIFIC RESTRICTIONS. THESE RESTRICTIONS MAY ONLY BE LIFTED BY A REVISED NOTICE OF AWARD.

**RESTRICTION:** This award is issued without a Federalwide Assurance (FWA) of Protection for Human Subjects for the following institution(s)/site(s): University of Medicine 1, University of Public Health, National Health Laboratory; BURMA. Information on and instructions for submitting and negotiating a Federalwide Assurance are available at the OHRP website (<http://www.hhs.gov/ohrp/>). The recipient must submit the required Assurance documents to OHRP within 60 days of the issuance of this Notice of Award (NoA) via the OHRP website. The recipient must provide NIAID with the submission date of required Assurance documents to OHRP. The recipient is then responsible for notifying NIAID when OHRP has approved the Assurance and for providing the OHRP Assurance number.

No research involving human subjects may be conducted at any institution until OHRP has approved Assurances and the recipient has ensured that the research has received appropriate Institutional Review Board (IRB) approval.

No funds may be drawn down from the payment system and no obligations may be made against Federal funds for any research involving human subjects prior to NIAID's issuance of a revised Notice of Award to remove this restriction.

**Restriction:** This award is being issued **with** funds for the foreign component(s) at National Health Laboratory, Livestock Breeding & Veterinary Department, Vet Medicine and Disease Control, and Yangon University of Distance Education; BURMA as well as, University of Health Sciences, Ministry of Health, and Dept. of Livestock and Fisheries, Ministry of Ag and Forest; LAOS.

No funds may be expended or drawn down in the Payment Management System for the foreign site pending the resolution of internal administrative issues. Once these issues have been resolved, this award may be revised to allow use of funding for the portion of the study originally planned for the foreign site.

\*\*\*\*\*

**Restriction:** This award is made based on the interinstitutional agreement (IIA) between the recipient and Tufts University, which has been approved by the Office of Laboratory Animal Welfare (OLAW) in accordance with the PHS Policy on Humane Care and Use of Laboratory Animals. If there are any changes to this IIA, the recipient must notify OLAW and NIAID within 15 days of the change and no further charges for research involving live vertebrate animals may be incurred on this award without prior approval by OLAW and by NIAID.

\*\*\*\*\*

The recipient must conduct or arrange for the conduct of onsite subrecipient facility inspections every 6 months to ensure that subaward activities are being properly executed. The recipient

must provide certification in the Research Performance Progress Report that it is in compliance with this term and condition of award.

\*\*\*\*\*

The recipient must provide NIAID with copies of FSRS reporting of all (existing and newly established) subaward agreements within 30 days of submitting to FSRS.

\*\*\*\*\*

The recipient must provide NIH with copies of updated subaward agreements within 30 days of execution of any initial and subsequent subaward agreement(s). The subaward agreements must demonstrate compliance with the NIH Grants Policy Statement (NIH GPS) 15.2.1 Written Agreement. The subaward agreements must state the correct F&A rate which, for foreign subrecipients is 8% (see NIH GPS 16.6) and include descriptions of the biosafety monitoring plans for each project, where appropriate.

Failure to comply with this special condition can result in withholding of support, audit disallowances, suspension and/or termination of this award, and/or other appropriate enforcement actions. This award is subject to the Transparency Act subaward reporting requirement of 2 CFR Part 170, which must be reported through the Federal Funding Accountability and Transparency Subaward Reporting System (FSRS).

\*\*\*\*\*

The recipient is required to submit semi-annual progress reports, Research Performance Progress Report (RPPR), and Federal Financial Reports (FFR) to NIAID via the Request for Additional Materials module within eRA. The semi-annual reports for this budget period is due on **March 01**, 2023. NIAID will initiate a RAM request within eRA at least 15 days prior to the due date of the semi-annual progress report, RPPR and FFR. Upon receipt of the RAM request, the recipient is required to upload the requested documents in Commons within RAM no later than the due date listed above.

\*\*\*\*\*

The authority for automatic no-cost extension has been removed for this award. The recipient must request and receive written prior approval from NIAID before any extension of the final budget period.

\*\*\*\*\*

The recipient must request and receive written prior approval from NIAID to carry over any unobligated balance from one budget period to any subsequent budget period.

\*\*\*\*\*

The budget period anniversary start date for future year(s) will be **September 1**.

\*\*\*\*\*

The recipient must notify the US Embassy in Burma/Myanmar prior to any travel to that country.

\*\*\*\*\*

This Notice of Award (NoA) includes funds for **Oxford University Clinical Research Unit - VIETNAM** in the amount of **\$61,935**

This Notice of Award (NoA) includes funds for **Lao Oxford Mahosot Hospital Wellcome Trust Research Unit - LAOS** in the amount of **\$73,165**

This Notice of Award (NoA) includes funds for **National Institute of Veterinary Research - VIETNAM** in the amount of **\$18,876**

This Notice of Award (NoA) includes funds for **Institute of Ecology and Biological Resources (IEBR), Vietnam Academy of Sciences and Technology - VIETNAM** in the amount of **\$18,876**

This Notice of Award (NoA) includes funds for **Duke NUS - SINGAPORE** in the amount of **\$116,442**

\*\*\*\*\*

Research conducted at the following site(s) must be reported in the Research Performance Progress Report (RPPR), Section G.9 (Foreign component):

**Institute of Ecology and Biological Resources (IEBR), Vietnam Academy of Sciences and Technology - VIETNAM**

**Oxford University Clinical Research Unit - VIETNAM**

**National Institute of Veterinary Research - VIETNAM**

**Duke NUS - SINGAPORE**

**Lao Oxford Mahosot Hospital Wellcome Trust Research Unit - LAOS**

**Dept. of Livestock and Fisheries, Ministry of Ag and Forest - LAOS**

**University of Health Sciences, Ministry of Health - LAOS**

**UNIVERSITY OF MEDICINE 1 - BURMA**

**University of Public Health - BURMA**

**University of Mandalay - BURMA**

**Livestock Breeding & Veterinary Department, Vet MEDicine and Disease Control - BURMA**

**Yangon University of Distance Education - BURMA**

**National Health Laboratory - BURMA**

**Commonwealth Sci & Ind Res Org - Geelong - AUSTRALIA**

\*\*\*\*\*

This award includes human subject research studies and must conform to the DHHS policies for the [Protection of Human Subjects](#) research, which are a term and condition of award. Human subjects research is covered by the 2018 Common Rule, and may not be initiated until the associated protocols have received IRB approval as specified in [45 CFR 46](#). Failure to comply with the terms and conditions of award may result in the disallowance of costs and/or additional enforcement actions as outlined in Section 8.5 of the NIH Grants Policy Statement.

\*\*\*\*\*

Highly Pathogenic Agents:

NIAID defines a Highly Pathogenic Agent as an infectious Agent or Toxin that may warrant a biocontainment safety level of BSL3 or higher according to the current edition of the CDC/NIH Biosafety in Microbiological and Biomedical Laboratories (BMBL)

(<https://www.cdc.gov/labs/BMBL.html>). Research funded under this grant must adhere to the BMBL, including using the BMBL-recommended biocontainment level at a minimum. If the Institutional Biosafety Committee (IBC) (or equivalent body) or designated institutional biosafety official recommends a higher biocontainment level, the higher recommended containment level must be used.

When submitting future Progress Reports indicate at the beginning of the report:

If no research with a Select Agent (see 42 CFR 73 for the relevant human Select Agents and Toxins; and 7 CFR 331 and 9 CFR 121 for the relevant animal and plant Select Agents and Toxins at <https://www.selectagents.gov/regulations/> and <https://www.selectagents.gov/sat/list.htm>) and/or has been performed or is planned to be performed under this grant.

If the IBC or equivalent body or official has determined, for example, by conducting a risk assessment, that the work being planned or performed under this grant may be conducted at a biocontainment safety level that is lower than BSL3.



If the work involves Select Agents and/or Highly Pathogenic Agents, also address the following points:

Any NIAID pre-approved changes in the use of the Select Agents and/or Highly Pathogenic Agents including its restricted experiments that have resulted in a change in the required biocontainment level, and any resultant change in location, if applicable, as determined by the IBC or equivalent body or official.

If work with a new or additional Select Agents and/or Highly Pathogenic Agents is proposed in the upcoming project period, provide:

- A list of the new and/or additional Agent(s) that will be studied;
- A description of the work that will be done with the Agent(s), and whether or not the work is a restricted experiment;
- The title and location for each biocontainment resource/facility, including the name of the organization that operates the facility, and the biocontainment level at which the work will be conducted, with documentation of approval by the IBC or equivalent body or official. It is important to note if the work is being done in a new location;
- Any biosafety incidents that occurred and were reported to NIH/NIAID.

**SPREADSHEET SUMMARY**

**AWARD NUMBER:** 1R01AI163118-01A1

**INSTITUTION:** EcoHealth Alliance

Budget	Year 1	Year 2	Year 3	Year 4	Year 5
Salaries and Wages	\$106,941	\$106,941	\$106,941	\$106,941	\$106,941
Fringe Benefits	\$37,387	\$37,387	\$37,387	\$37,387	\$37,387
Personnel Costs (Subtotal)	\$144,328	\$144,328	\$144,328	\$144,328	\$144,328
Consultant Services	\$18,864	\$18,864	\$18,864	\$18,864	\$18,864
Materials & Supplies	\$35,590	\$35,590	\$35,530	\$35,530	\$35,290
Travel	\$29,062	\$29,062	\$29,062	\$29,062	\$29,062
Subawards/Consortium/Contractual Costs	\$289,293	\$289,476	\$289,476	\$289,119	\$291,585
Publication Costs	\$2,240	\$3,360	\$3,360	\$4,480	\$2,240
<b>TOTAL FEDERAL DC</b>	<b>\$519,377</b>	<b>\$520,680</b>	<b>\$520,620</b>	<b>\$521,383</b>	<b>\$521,369</b>
<b>TOTAL FEDERAL F&amp;A</b>	<b>\$134,015</b>	<b>\$95,165</b>	<b>\$90,354</b>	<b>\$90,792</b>	<b>\$89,823</b>
<b>TOTAL COST</b>	<b>\$653,392</b>	<b>\$615,845</b>	<b>\$610,974</b>	<b>\$612,175</b>	<b>\$611,192</b>

Facilities and Administrative Costs	Year 1	Year 2	Year 3	Year 4	Year 5
F&A Cost Rate 1	39.09%	39.09%	39.09%	39.09%	39.09%
F&A Cost Base 1	\$342,836	\$243,452	\$231,144	\$232,264	\$229,784
F&A Costs 1	\$134,015	\$95,165	\$90,354	\$90,792	\$89,823